{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Praxis Precision Medicines, Inc.
Is Praxis Precision Medicines, Inc. technically bullish or bearish?
As of October 24, 2025, Praxis Precision Medicines, Inc. has a mildly bullish technical trend, supported by bullish moving averages and Bollinger Bands, despite bearish RSI readings and long-term underperformance compared to the S&P 500.
Is Praxis Precision Medicines, Inc. technically bullish or bearish?
As of October 24, 2025, Praxis Precision Medicines, Inc. shows a mildly bullish trend with positive momentum from MACD and moving averages, but caution is advised due to bearish RSI readings.
Is Praxis Precision Medicines, Inc. technically bullish or bearish?
As of October 24, 2025, Praxis Precision Medicines, Inc. has a mildly bullish technical trend, with mixed indicators across time frames, while significantly outperforming the S&P 500 with returns of 255.26% over the past month and 146.73% over the past year.
Praxis Precision Medicines Hits Day High with 14.47% Surge in Stock Price
Praxis Precision Medicines, Inc. has seen notable stock activity, with significant gains reported recently. While the company has struggled with profitability and year-to-date performance, it has shown resilience over the past three years, outperforming broader market indices during that period. Today's fluctuations underscore its current volatility and recovery potential.
Is Praxis Precision Medicines, Inc. technically bullish or bearish?
As of August 4, 2025, Praxis Precision Medicines, Inc. shows a mildly bearish technical trend, with bearish daily moving averages and MACD indicators, underperforming the S&P 500 significantly year-to-date and over the past year.
Is Praxis Precision Medicines, Inc. overvalued or undervalued?
As of August 9, 2023, Praxis Precision Medicines, Inc. is considered risky and overvalued due to significant losses and poor financial metrics, underperforming the S&P 500 with a return of -23.83% compared to the index's 17.14%.
Praxis Precision Medicines Hits Day High with Strong 7.28% Intraday Surge
Praxis Precision Medicines, Inc. has seen a significant intraday increase, reaching a high of USD 40.58. However, the company faces ongoing financial challenges, including negative operating cash flow and a low return on equity. Its performance over the past year and year-to-date has been notably unfavorable compared to the S&P 500.
Is Praxis Precision Medicines, Inc. overvalued or undervalued?
As of August 9, 2023, Praxis Precision Medicines, Inc. is considered overvalued and rated as "risky," with key financial metrics indicating poor performance, including a Price to Book Value of 2.07, an EV to EBITDA of -2.50, and a year-to-date return of -45.91%.
Is Praxis Precision Medicines, Inc. technically bullish or bearish?
As of June 10, 2025, the technical outlook is neutral with mixed indicators, showing mildly bullish weekly and monthly MACD, but bearish signals from Bollinger Bands and daily moving averages, resulting in no strong directional bias.
Who are in the management team of Praxis Precision Medicines, Inc.?
As of March 2022, the management team of Praxis Precision Medicines, Inc. includes Mr. Kiran Reddy, who is the Co-Founder and Director of the company.
What does Praxis Precision Medicines, Inc. do?
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. It has a market cap of $885.24 million and reported a net profit loss of $69 million as of March 2025.
How big is Praxis Precision Medicines, Inc.?
As of Jun 18, Praxis Precision Medicines, Inc. has a market capitalization of 885.24 million and reported net sales of 8.12 million with a net profit of -212.57 million over the latest four quarters. Shareholder's funds are 445.45 million and total assets are 483.11 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
